Resveratrol-Exemestane Beneficial Regimen to Overcome the Complications over Existing Therapies for the Management of Breast Cancer
Author:
Affiliation:
1. Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India
Abstract
Publisher
Bentham Science Publishers Ltd.
Subject
Molecular Biology,Molecular Medicine,General Medicine,Biochemistry
Reference12 articles.
1. Mathur P.; Sathishkumar K.; Chaturvedi M.; Cancer statistics, 2020: Report from national cancer registry programme, India. JCO Glob Oncol 2020,6(6),1063-1075
2. Lloyd M.R.; Wander S.A.; Hamilton E.; Razavi P.; Bardia A.; Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: Current and emerging role. Ther Adv Med Oncol 2022,14,1-25
3. Gupta P.; Neupane Y.R.; Parvez S.; Kohli K.; Sultana Y.; Combinatorial chemosensitive nanomedicine approach for the treatment of breast cancer. Curr Mol Med 2023,23,1-13
4. Bradley R.; Braybrooke J.; Gray R.; Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022,23(3),382-392
5. Xu L.; Jiang W.; Li W.; Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis. Exp Ther Med 2022,24(3),575
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3